

October 2025

Dear Pharmacist

Discovery Health recognises the important role you play in delivering care to members of the medical schemes we administer. We want to support the incredible work you do for our members. Part of this includes keeping you up to date on essential changes.

To show our commitment to your practice and patients, we are pleased to share that we have revised the Chronic Disease List (CDL) formulary for 2026. (The Chronic Disease List is a list of conditions that Discovery Health Medical Scheme covers on all plans, as defined in the laws on Prescribed Minimum Benefits.)

We base our formulary updates on clinical best practice and evidence-based reviews to ensure clinical integrity, regulatory compliance and financial sustainability to the Scheme. Keeping the formulary updated means that members have fair access to essential medicines while our benefits stay affordable and sustainable.

We've enhanced the formulary for 2026 by adding 143 new products. You can view the products that we've replaced with preferentially priced generic or therapeutic equivalents in the Chronic Illness Benefit provisional formulary for 2026 [here](#).

Key additions to the formulary

Additions to all health plans, except KeyCare

- Cardiovascular
 - First-to-market generic of flecainide – Tempacin® CR 100 mg, CR 200 mg
 - Multiple rivaroxaban generics for dysrhythmias

Additions to all health plans

- Glaucoma
 - First-to-market generic for bimatoprost – Bimapres®
 - Timolol combinations – Dorzopt forte®, Ocutra Co®
- Inflammatory bowel disease
 - First-to-market mesalazine SRT generics – Zylamene® SR 800 mg, SR 1200 mg

We have deleted 85 products from the current chronic formulary, due to discontinuation, unavailability or non-preferential pricing.

Key deletions which may require switches to other formulary alternatives for a fully funded option

NB: Generic or therapeutic alternatives exist for all deleted formulary items.

Deletions for Core, Saver, Priority and Smart plans

- Cardiovascular
 - Prexum® 10 plus 10/2.5 mg (perindopril-indapamide combination)
 - Myoprin® 100 mg (aspirin tablet) – 100 mg enteric coated formulary alternatives available

Deletions for all plans, except Comprehensive and Executive plans

- Respiratory
 - Dulera® 100/5 mcg, 200/5 mcg (mometasone-formoterol combination)
 - Seebri Breezhaler® (glycopyrronium)
 - Ultibro Breezhaler® (indacaterol-glycopyrronium combination)

Deletions for all health plans

- Cardiovascular
 - Sotahexal® 80 mg, 160 mg – to be discontinued by the manufacturer in December 2025
 - Prexum® 5 plus 5/2.5 mg (perindopril-indapamide combination)
- Diabetes
 - Synglutra® 10/1000 (dapagliflozin-metformin combination)
- Respiratory
 - Theophylline Kiara® 200 mg, 300 mg – deleted in accordance with updated respiratory guidelines

Your role in enhancing patient care

By dispensing medicines listed on the 2026 formulary, you will help your patients avoid co-payments (the amount they must pay from their own pocket). This will lessen their financial burden while making sure they still get high-quality treatment. It also means you can keep giving them excellent care and improving their health outcomes.

For more details about the formulary and payment structures for 2026, please log in to the Healthcare Professional Zone on [the Discovery website](#) and access MedAdvisor. Click **Tools > Health Tools > Medicine Adviser** from October 2025.

We've attached a quick reference guide with formulary medicine additions, deletions and plan-type changes, to help you understand the changes made to this formulary (medicine list).

If you have questions or need help, please email us at healthpartnerinfo@discovery.co.za or visit the [Healthcare Professional Zone](#) on our website.

Thank you for your dedication to the health of our members. Your commitment to staying updated is vital to making sure we deliver the highest standard of care, together.

Regards



Suzanne van der Walt

Manager: Contracts and Network Strategy Management
Strategic Risk Management
Discovery Health